Alter NRG Corp. (ANRGF: OTCQX International) | Alter NRG

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Alter NRG Corp. (ANRGF: OTCQX International) | Alter NRG Corp. completes share consolidation Alter NRG Corp. completes share consolidation

Alter NRG Corp. completes share consolidation

Canada NewsWire

TSX - NRG
OTCQX - ANRGF

CALGARY , June 26, 2014 /CNW/ - Alter NRG Corp. ("Alter NRG" or the "Company") announces that it has completed the consolidation of its common shares on a ratio of four (4) existing common shares for one (1) new common share (the "Share Consolidation"). The Share Consolidation had previously been approved by Alter NRG's shareholders at its annual and special general meeting held on June 13 , 2014. 

The Share Consolidation was announced on May 27, 2014 and in that press release Walter Howard , CEO of Alter NRG, stated that "Alter NRG has achieved significant milestones and continues to attract commercial attention and new customers worldwide. However, in the capital markets we are often overlooked and share price is a contributing factor as many investors cannot invest in stocks below a certain price. I believe that a reverse split will allow a greater number of investors to evaluate an open market investment in Alter NRG and it will also provide us the flexibility to list on an exchange in a larger capital market should we choose to do so."

The Company has received approval from the Toronto Stock Exchange ("TSX") to effect the consolidation and it is expected that the post-consolidation common shares will begin trading on the TSX at the opening of market on June 30, 2014 , under the same stock symbol: NRG. 

Letters of transmittal, describing the process by which shareholders may obtain new certificates representing their consolidated common shares, have been mailed to the Company's registered shareholders. All registered shareholders will be required to send their share certificates representing pre-consolidation common shares, along with a properly executed letter of transmittal, to the Company's transfer agent, Valiant Trust Company at either, 600 – 750 Cambie Street, Vancouver, BC V6B 0A2 or Suite 710, 130 King Street SW, Toronto, ON M5X 1A9.  Shareholders who hold their shares through a broker or other intermediary and do not have shares registered in their name will not need to complete a letter of transmittal.  No fractional shares will be issued under the share consolidation.  If as a result of the Share Consolidation a holder would otherwise be entitled to a fraction of a common share, the number of shares post-consolidation shares the holder will receive will be rounded up if the fractional share is equal to or greater than 0.5 and rounded down if the fraction is less than 0.5  Each registered holder will have his holdings aggregated and will be entitled to receive only one whole common share for any fractional interest resulting from the consolidation of his holdings, as determined on an aggregated basis.  All outstanding options, restricted share units and performance share units will be adjusted accordingly.

ABOUT ALTER NRG

Alter NRG provides alternative energy solutions to meet the growing demand for environmentally responsible and economically viable energy in world markets. Alter NRG's primary objective is to further commercialize the Westinghouse Plasma Gasification Technology, through its wholly owned subsidiary, to provide renewable and clean energy solutions from a wide variety of feedstocks, and to provide a wide variety of energy outputs – including liquid fuels like ethanol and diesel, electrical power, and syngas.

The Toronto Stock Exchange does not accept responsibility for the adequacy or accuracy of this release.

Advisory Respecting Forward-Looking Statements:
This news release contains certain "forward-looking information and statements" within the meaning of applicable securities laws.  The use of any of the words "expect", "anticipate", "continue", "objective", "may", "will", "project", "should", "believe", "intends", and similar expressions are intended to identify forward-looking information or statements.  In particular, this new release contains forward looking statements pertaining to Alter NRG's future business strategy, listing the Company's common shares on another exchange, the trading date of the post-consolidation common shares and the process for shareholders obtaining new share certificates.  Various assumptions were used in conclusions or making the projections contained in the forward-looking statements throughout this news release.

The forward-looking information and statements included in this news release are not guarantees of future performance and should not be unduly relied upon. Forward-looking statements reflect management's current beliefs and assumptions, based on information currently available to management. A number of factors could cause actual results to differ materially from the results discussed in the forward-looking statements, many of which are beyond the control of the Company. Among the material factors that could cause actual results to differ materially from those indicated by such forward-looking statements are: the projects do not get required approvals, that projects do not get financing, that there may be competition in those markets, as well as those factors discussed in or referred to under the heading "Risk Factors" in the Company's Annual Information Form dated March 27, 2014 available at www.sedar.com . Such information and statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information or statements.

The Company cautions that the foregoing list of assumptions, risks and uncertainties is not exhaustive. The forward-looking information and statements contained in this news release speak only as of the date of this news release, and the Company assumes no obligation to publicly update or revise them to reflect new events or circumstances, except as may be required pursuant to applicable securities laws.

SOURCE Alter NRG Corp.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 62

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 271

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 718

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 135

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 255

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 410

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 105

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 325

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 139

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 190

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading

Top 5 Most Recently Viewed Articles

IONQ Achieves Record Stock Levels Amid Strong Growth Indicators

Updated Category News Views 243

IONQ Stock Reaches New Heights Recently, IONQ has made headlines as its stock skyrocketed to an unprecedented level of $47.41, marking a significant achievement for the company. With a robust market capitalization of $10.2 billion, this remarkable performance is a testament to the company's impressive growth trajectory and the strong belief investors hold in its future....

Continue Reading
Model 1 Commercial Vehicles Expands Leadership Team for Growth

Updated Category News Views 285

Model 1 Commercial Vehicles Announces Leadership Changes Model 1 Commercial Vehicles is thrilled to unveil a set of key leadership appointments aimed at enhancing its strategic direction and ensuring the company's ongoing success. These changes reflect the impressive growth trajectory the company has experienced over the past few years. Tony Matijevich Takes the Helm as...

Continue Reading
Texas Instruments: Unusual Options Trends Uncovered

Updated Category News Views 195

Texas Instruments Options Insights Financial powerhouses have made a notable bullish move on Texas Instruments. Our analysis reveals intriguing trends within the options market for Texas Instruments (NASDAQ: TXN), showcasing an unusual number of trades that pinpoint shifting market sentiments. Trading Sentiment Overview Diving deeper into the data, it appears that 58% of...

Continue Reading
SMCP Unveils Latest Interim Financial Report for 2025

Updated Category News Views 177

SMCP Announces Availability of Its Interim Financial Report SMCP is excited to share that its interim financial report for the six-month period ending June 30, 2025, is now available for public access. This report has been officially filed with the relevant regulatory authorities. Details on the Financial Report This financial report outlines the company's performance...

Continue Reading
Kevin O'Leary Discusses Business Leaders' Support for Trump

Updated Category News Views 159

Understanding O'Leary's Perspective on Business Leadership Kevin O’Leary, a prominent entrepreneur and investor from Shark Tank, has provided insight into the evolving relationship between business leaders and President Trump. In recent discussions, O’Leary emphasized that the admiration many tech CEOs and corporate leaders have for Trump is not solely about his tax...

Continue Reading